Oral exemestane 25 mg/day for 2–3 years of adjuvant therapy was generally more effective than 5 years of continuous adjuvant tamoxifen in the treatment of postmenopausal women with early-stage estrogen receptor-positive/unknown receptor status breast in a large well-designed [ citation needed ] trial. Preliminary data from the open-label TEAM trial comparing exemestane with tamoxifen indicated in 2009 that exemestane 25 mg/day is also effective in the primary adjuvant treatment of early-stage breast cancer in postmenopausal women. 
Athletes abuse amphetamines because they experience a decreased sense of fatigue. However, athletes do sustain increases in blood pressure, increases in heart rate, redistribution of blood flow to skeletal muscles, and mobilization of energy substrates. One of the uses of amphetamines is to promote weight loss. This can be dangerous because it can cause body fat percent to drop to dangerous levels in some athletes. Amphetamines suppress hunger and can increase the risk of athletes reducing glycogen This may reduce the performance capabilities of athletes. Amphetamine abuse by athletes is not recommended and any athlete using these drugs should be counseled.
Tibolone has tissue -selective estrogenic effects, with desirable effects in bone , the brain , and the vagina , and lack of undesirable action in the endometrium and breasts .  Its tissue selectivity is the result of metabolism , enzyme modulation (., of estrogen sulfatase and estrogen sulfotransferase ), and receptor modulation that vary in different target tissues, and differs mechanistically from that of selective estrogen receptor modulators (SERMs) such as tamoxifen , which produce their tissue-selectivity via means of modulation of the ER.   As such, to distinguish it from SERMs, tibolone has been described as a "selective tissue estrogenic activity regulator" (STEAR),  and also as a "selective estrogen enzyme modulator" (SEEM).